

# Adenocarcinoma of the esophagogastric junction: incidence and treatment strategies

Gastric Cancer

13, 63-73

DOI: [10.1007/s10120-010-0555-2](https://doi.org/10.1007/s10120-010-0555-2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Update on HER2 testing for breast and upper gastrointestinal tract cancers. <i>Biomarkers in Medicine</i> , 2011, 5, 307-318.	0.6	25
2	Survival of stomach and esophagus cancer patients in Germany in the early 21st century. <i>Acta Oncologica</i> , 2012, 51, 906-914.	0.8	37
3	Changing Pattern of Adenocarcinoma of the Esophagogastric Junction in Recent 10 Years: Experience at a Large Tertiary Medical Center in China. <i>Tumori</i> , 2012, 98, 568-574.	0.6	6
4	Clinicopathological Features and Prognostic Factors of Adenocarcinoma of the Esophagogastric Junction According to Siewert Classification: Experiences at a Single Institution in Japan. <i>Annals of Surgical Oncology</i> , 2012, 19, 677-683.	0.7	101
5	Impact of esophageal invasion on clinicopathological characteristics and long-term outcome of adenocarcinoma of the subcardia. <i>Journal of Surgical Oncology</i> , 2012, 106, 856-861.	0.8	5
6	Lymph node metastasis from cancer of the esophagogastric junction, and determination of the appropriate nodal dissection. <i>Surgery Today</i> , 2012, 42, 351-358.	0.7	37
7	Gastric Tube Reconstruction Reduces Postoperative Gastroesophageal Reflux in Adenocarcinoma of Esophagogastric Junction. <i>Digestive Diseases and Sciences</i> , 2012, 57, 738-745.	1.1	30
8	Reply to Letter to the Editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett's esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First). <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 291-292.	1.3	2
9	Adenocarcinomas of the esophagogastric junction: experiences at a single institution in China. <i>World Journal of Surgical Oncology</i> , 2013, 11, 155.	0.8	17
10	Validation of the application of the Japanese curative criteria for superficial adenocarcinoma at the esophagogastric junction treated by endoscopic submucosal dissection: a long-term analysis. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 2436-2445.	1.3	23
11	Priority of Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction. <i>Annals of Surgical Oncology</i> , 2013, 20, 4252-4259.	0.7	49
12	Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction. <i>Journal of Surgical Oncology</i> , 2013, 108, 542-549.	0.8	16
13	Esophagus or Stomach? The Seventh TNM Classification for Siewert Type II/III Junctional Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 773-779.	0.7	38
14	Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma. <i>American Journal of Surgery</i> , 2013, 205, 711-717.	0.9	14
15	Surgical Management of Gastroesophageal Junction Tumors. <i>Seminars in Radiation Oncology</i> , 2013, 23, 16-23.	1.0	14
16	Ratio of Metastatic to Examined Lymph Nodes, a Helpful Staging System and Independent Prognostic Factor of Esophagogastric Junction Cancer. <i>PLoS ONE</i> , 2013, 8, e73238.	1.1	9
17	Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction. <i>PLoS ONE</i> , 2014, 9, e88010.	1.1	9
18	The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction. <i>Journal of Surgical Oncology</i> , 2014, 110, 333-340.	0.8	50

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of TAZ and $\beta$ -catenin expression in adenocarcinoma of the esophagogastric junction. <i>Diagnostic Pathology</i> , 2014, 9, 125.	0.9	21
20	A nomogram for predicting individual survival of patients with gastric cancer who underwent radical surgery with extended lymph node dissection. <i>Gastric Cancer</i> , 2014, 17, 287-293.	2.7	65
21	Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients. <i>Gastric Cancer</i> , 2014, 17, 54-60.	2.7	4
22	Nomogram predicted survival of patients with adenocarcinoma of esophagogastric junction. <i>World Journal of Surgical Oncology</i> , 2015, 13, 197.	0.8	35
23	Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. <i>World Journal of Gastroenterology</i> , 2015, 21, 9999.	1.4	21
24	Comparisons Between Different Procedures of No. 10 Lymphadenectomy for Gastric Cancer Patients With Total Gastrectomy. <i>Medicine (United States)</i> , 2015, 94, e1305.	0.4	9
25	Evaluation of MMP-9 and MMP-2 and their suppressor TIMP-1 and TIMP-2 in adenocarcinoma of esophagogastric junction. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4343-4349.	1.0	19
26	Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial. <i>Digestive Surgery</i> , 2016, 33, 424-430.	0.6	4
27	Expression analysis of the TGF- $\beta$ /SMAD target genes in adenocarcinoma of esophagogastric junction. <i>Open Medicine (Poland)</i> , 2016, 11, 83-86.	0.6	3
28	The length of proximal margin does not influence the prognosis of Siewert type II/III adenocarcinoma of esophagogastric junction after transhiatal curative gastrectomy. <i>SpringerPlus</i> , 2016, 5, 588.	1.2	8
29	Changes of Esophagogastric Junctional Adenocarcinoma and Gastroesophageal Reflux Disease Among Surgical Patients During 1988-2012. <i>Annals of Surgery</i> , 2016, 263, 88-95.	2.1	117
30	Laparoscopic Proximal Gastrectomy with Double-Tract Reconstruction by Intracorporeal Anastomosis with Linear Staplers. <i>Journal of the American College of Surgeons</i> , 2016, 222, e39-e45.	0.2	23
31	Reduced MUTYH, MTH1, and OGG1 expression and TP53 mutation in diffuse-type adenocarcinoma of gastric cardia. <i>Human Pathology</i> , 2016, 52, 145-152.	1.1	11
32	Laparoscopic lymphadenectomy around the left renal vein (16a2lat) by tunneling under the pancreas for advanced Siewert type II adenocarcinoma. <i>Surgery Today</i> , 2016, 46, 1108-1113.	0.7	2
33	Laparoscopic mediastinal dissection via an open left diaphragm approach for advanced Siewert type II adenocarcinoma. <i>Surgery Today</i> , 2016, 46, 129-134.	0.7	16
34	Western strategy for EGJ carcinoma. <i>Gastric Cancer</i> , 2017, 20, 60-68.	2.7	47
35	Different time trend and management of esophagogastric junction adenocarcinoma in three Asian countries. <i>Digestive Endoscopy</i> , 2017, 29, 18-25.	1.3	34
36	Siewert III adenocarcinoma: treatment update. <i>Updates in Surgery</i> , 2017, 69, 319-325.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma: a propensity score-matched case-control study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 3495-3503.	1.3	30
38	Prognostic performance of three lymph node staging schemes for patients with Siewert type II adenocarcinoma of esophagogastric junction. <i>Scientific Reports</i> , 2017, 7, 10123.	1.6	18
39	New evidence guiding extent of lymphadenectomy for esophagogastric junction tumor. <i>Medicine (United States)</i> , 2017, 96, e6533.	0.4	8
40	A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. <i>Experimental and Molecular Medicine</i> , 2017, 49, e383-e383.	3.2	1
41	Predictive Value of Stemness Factor Sox2 in Gastric Cancer Is Associated with Tumor Location and Stage. <i>PLoS ONE</i> , 2017, 12, e0169124.	1.1	13
42	The esophagogastric junctional adenocarcinoma an increasing disease. <i>Journal of Thoracic Disease</i> , 2017, 9, 1455-1458.	0.6	8
43	Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?. <i>Gastric Cancer</i> , 2018, 21, 303-314.	2.7	70
44	Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea. <i>Journal of Gastric Cancer</i> , 2018, 18, 328.	0.9	12
45	Adenocarcinoma of the esophagogastric junction and its background mucosal pathology: A comparative analysis according to Siewert classification in a Japanese cohort. <i>Cancer Medicine</i> , 2018, 7, 5145-5154.	1.3	15
46	Short-term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction. <i>Thoracic Cancer</i> , 2018, 9, 1018-1025.	0.8	2
47	Analysis of the clinicopathological features and prognostic factors in 734 cases of Chinese Hui and Han patients with adenocarcinoma of the esophagogastric junction. <i>Surgical Oncology</i> , 2018, 27, 556-562.	0.8	7
48	Clinicopathological Characteristics and Prognosis of Proximal and Distal Gastric Cancer during 1997-2017 in China National Cancer Center. <i>Journal of Oncology</i> , 2019, 2019, 1-13.	0.6	22
49	Staging of Gastric Cancer: Current Revision and Future Proposal. , 2019, , 45-55.		0
50	Robotic-assisted gastrectomy for gastric cancer: a European perspective. <i>Gastric Cancer</i> , 2019, 22, 909-919.	2.7	55
51	Esophagogastric Junction (EGJ) Carcinoma: An Updated Review. <i>GI Surgery Annual</i> , 2019, , 1-62.	0.0	0
53	Robotic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 2357-2363.	1.3	30
54	Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial. <i>BMC Cancer</i> , 2019, 19, 283.	1.1	12
55	Clinical application and observation of modified Ivor-Lewis surgery in Siewert type II adenocarcinoma of the Esophagogastric junction. <i>Journal of Cardiothoracic Surgery</i> , 2019, 14, 207.	0.4	5

#	ARTICLE	IF	CITATIONS
56	Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction. <i>Medicine (United States)</i> , 2019, 98, e18451.	0.4	7
57	Prognostic effect of different etiologies in patients with gastric cardia cancer. <i>Medicine (United States)</i> , 2019, 98, e18451.	0.4	7
58	Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option. <i>Journal of International Medical Research</i> , 2019, 47, 398-410.	0.4	5
59	A Case of Alpha-Fetoprotein-Producing Adenocarcinoma of the Esophagogastric Junction in which Long-Term Survival Was Achieved by Means of Individualized Multidisciplinary Therapy. <i>Journal of Gastrointestinal Cancer</i> , 2019, 50, 617-620.	0.6	3
60	True esophagogastric junction adenocarcinoma: background of its definition and current surgical trends. <i>Surgery Today</i> , 2020, 50, 809-814.	0.7	26
61	The Postoperative outcomes of thoracoscopic-laparoscopic Ivor-Lewis surgery plus D2 celiac lymphadenectomy for patients with adenocarcinoma of the esophagogastric junction. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4957-4966.	1.3	4
62	Long-term outcomes and prognostic factor analysis of resected Siewert type II adenocarcinoma of esophagogastric junction in China: a seven-year study. <i>BMC Surgery</i> , 2020, 20, 302.	0.6	7
63	The Prognostic Value of the Prognostic Nutritional Index (PNI) in Radically Resected Esophagogastric Junction Adenocarcinoma. <i>Nutrition and Cancer</i> , 2021, 73, 2589-2596.	0.9	4
64	Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1590.	3.4	128
65	Laparoscopic-assisted left thoracoabdominal esophagectomy (LLTA): an innovative approach for locally advanced tumors of the gastroesophageal junction. <i>Ecological Management and Restoration</i> , 2020, 33, .	0.2	2
66	Detection of early adenocarcinoma of the esophagogastric junction by spraying an enzyme-activatable fluorescent probe targeting Dipeptidyl peptidase-IV. <i>BMC Cancer</i> , 2020, 20, 64.	1.1	12
67	Immunogenic characteristics of microsatellite instability-low esophagogastric junction adenocarcinoma based on clinicopathological, molecular, immunological and survival analyses. <i>International Journal of Cancer</i> , 2021, 148, 1260-1275.	2.3	4
68	Development and validation of a novel competing risk model for predicting survival of esophagogastric junction adenocarcinoma: a SEER population-based study and external validation. <i>BMC Gastroenterology</i> , 2021, 21, 38.	0.8	7
69	Predictors of Lymph Node Metastasis in Siewert Type II T1 Adenocarcinoma of the Esophagogastric Junction: A Population-Based Study. <i>Cancer Control</i> , 2021, 28, 107327482110266.	0.7	7
70	HN1L promotes invasion and metastasis of the esophagogastric junction adenocarcinoma. <i>Thoracic Cancer</i> , 2021, 12, 650-658.	0.8	9
71	Clinical and prognostic features of MMP-2 and VEGF in AEG patients. <i>Open Medicine (Poland)</i> , 2021, 16, 786-794.	0.6	1
72	The Early Diagnostic Value of Serum Interleukin-8 in Esophagogastric Junction Adenocarcinoma. <i>Cancer Control</i> , 2021, 28, 107327482110048.	0.7	1
73	Prognostic Nomogram for Postoperative Patients With Gastroesophageal Junction Cancer of No Distant Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 643261.	1.3	6

#	ARTICLE	IF	CITATIONS
74	Clinical characteristics and prediction model of long time survival of patients with stage M1 Siewert type II esophagogastric junction adenocarcinoma. <i>Translational Cancer Research</i> , 2021, 10, 2002-2008.	0.4	2
75	A novel risk score system for prognostic evaluation in adenocarcinoma of the oesophagogastric junction: a large population study from the SEER database and our center. <i>BMC Cancer</i> , 2021, 21, 806.	1.1	0
76	Identification of biomarkers associated with diagnosis and prognosis of gastroesophageal junction adenocarcinoma—a study based on integrated bioinformatics analysis in GEO and TCGA database. <i>Medicine (United States)</i> , 2020, 99, e23605.	0.4	7
77	Comprehensive Molecular Characterization of Adenocarcinoma of the Gastroesophageal Junction Between Esophageal and Gastric Adenocarcinomas. <i>Annals of Surgery</i> , 2022, 275, 706-717.	2.1	30
78	Rare Presentation of Gastroesophageal Carcinoma with Rectal Metastasis: A Case Report. <i>American Journal of Case Reports</i> , 2016, 17, 611-615.	0.3	8
79	Changing pattern of adenocarcinoma of the esophagogastric junction in recent 10 years: experience at a large tertiary medical center in China. <i>Tumori</i> , 2012, 98, 568-74.	0.6	8
80	Mixed adenoneuroendocrine carcinoma (MANEC) of the gastroesophageal junction: a case report and review of the literature. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 109, 160-162.	0.1	17
81	A prospective appraisal of preoperative body mass index in D2-resected patients with non-metastatic gastric carcinoma and Siewert type II/III adenocarcinoma of esophagogastric junction: results from a large-scale cohort. <i>Oncotarget</i> , 2017, 8, 68165-68179.	0.8	8
82	Surgical approach for Siewert type II adenocarcinoma of the esophagogastric junction: transthoracic or transabdominal? —a single-center retrospective study. <i>Annals of Translational Medicine</i> , 2018, 6, 450-450.	0.7	9
83	Lymph node metastasis in gastric cardiac adenocarcinoma in male patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 6245.	1.4	3
84	Adenocarcinoma of esophagogastric junction. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2014, 26, 362-3.	0.7	8
85	Intrathoracic esophagojejunostomy using OrVilâ„¢ for gastric adenocarcinoma involving the esophagus. <i>World Journal of Gastrointestinal Surgery</i> , 2014, 6, 235.	0.8	3
86	Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy. <i>Radiology</i> , 2022, 302, 129-137.	3.6	4
87	S2136â€¦Serendipitous Surveillance: A Case of Alpha-Fetoprotein-Producing Esophageal Adenocarcinoma in a Patient With Prior Seminoma. <i>American Journal of Gastroenterology</i> , 2021, 116, S918-S918.	0.2	0
88	Adenocarcinoma of the Esophagogastric Junction: Clinicopathological Characteristics. <i>The Korean Journal of Helicobacter and Upper Gastrointestinal Research</i> , 2012, 12, 141.	0.1	0
89	Psychometric Analysis of a Persian Version of the European Organization for Research and Treatment of Cancer OG25 Quality of Life Questionnaire in Oesophagogastric Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 2739-2745.	0.5	2
90	How to Treat EGJ Cancer: Indications and Treatment Strategy. , 2017, , 117-137.		0
91	Methylenetetrahydrofolate reductase tagging polymorphisms are associated with risk of esophagogastric junction adenocarcinoma: a case-control study involving 2,740 Chinese Han subjects. <i>Oncotarget</i> , 2017, 8, 111482-111494.	0.8	5

#	ARTICLE	IF	CITATIONS
92	Alpha-Fetoprotein-Producing Cancer That Derived in Barrett's Esophageal Cancer after Chemotherapy. Japanese Journal of Gastroenterological Surgery, 2018, 51, 29-39.	0.0	0
94	Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries. Digestion, 2022, 103, 29-36.	1.2	25
95	SURGICAL MANAGEMENT OF ADENOCARCINOMA OF ESOPHAGOGASTRIC JUNCTION - A TERTIARY CARE CENTRE EXPERIENCE IN SOUTH INDIA. , 2020, , 1-4.		0
96	Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration. Endoscopic Ultrasound, 2013, 2, 148-52.	0.6	4
97	Surgical and survival outcomes after laparoscopic and open gastrectomy for serosa-invasive Siewert type II/III esophagogastric junction carcinoma: a propensity score matching analysis. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5055-5066.	1.3	7
98	Survival Benefit of Pyloric Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Based on Tumor Diameter: A Large Cohort Study. Frontiers in Oncology, 2021, 11, 748694.	1.3	4
99	Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma. Anticancer Research, 2022, 42, 1051-1057.	0.5	0
100	The role of multispiral computed tomography in detecting and the assessment of the degree of damage of esophago-gastric junction cancer. Issledovaniya I Praktika V Medicine, 2022, 9, 65-76.	0.1	1
101	Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study. Radiation Oncology, 2022, 17, 45.	1.2	7
102	Serum metabolomic profiling for patients with adenocarcinoma of the esophagogastric junction. Metabolomics, 2022, 18, 26.	1.4	2
104	Trends in age-standardised net survival of stomach cancer by subsite and stage: A population-based study in Osaka, Japan, 2001-2014. Cancer Epidemiology, 2022, 79, 102170.	0.8	0
105	A phase 1b multicenter study of TAS-102 in combination with irinotecan in patients with advanced recurrent or unresectable gastric and gastroesophageal adenocarcinoma after at least one line of treatment with a fluoropyrimidine and platinum-containing regimen. Medical Oncology, 2022, 39, .	1.2	0
106	Should the splenic hilar lymph node be dissected for the management of adenocarcinoma of the esophagogastric junction?. European Journal of Surgical Oncology, 2022, , .	0.5	0
107	Total laparoscopic versus laparoscopic-assisted transabdominal posterior mediastinal digestive tract reconstruction in the treatment of Siewert II adenocarcinoma of the esophagogastric junction: A retrospective study. Frontiers in Surgery, 0, 9, .	0.6	0
108	Model established based on blood markers predicts overall survival in patients after radical resection of types II and III adenocarcinoma of the esophagogastric junction. World Journal of Gastrointestinal Surgery, 2022, 14, 788-798.	0.8	0
109	Upper Gastrointestinal Cancers in Rwanda: Epidemiological, Clinical and Histopathological Features in Patients Presenting to a Tertiary Referral Hospital. Open Journal of Gastroenterology, 2022, 12, 286-298.	0.1	2
110	Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature. JAMA Surgery, 2023, 158, 10.	2.2	6
111	Hand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion. Surgical Endoscopy and Other Interventional Techniques, 2023, 37, 4104-4110.	1.3	1

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------